Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214


Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.

Willey CD, Xiao D, Tu T, Kim KW, Moretti L, Niermann KJ, Tawtawy MN, Quarles CC, Lu B.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1518-26. doi: 10.1016/j.ijrobp.2009.06.044.


Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.

Dudek AZ, Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Farassati F.

Invest New Drugs. 2008 Feb;26(1):13-24.


Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.

Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, Lu B.

Cancer Res. 2006 Dec 1;66(23):11409-15.


Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.

Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B.

Clin Cancer Res. 2009 Oct 1;15(19):6096-105. doi: 10.1158/1078-0432.CCR-09-0589.


Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.

Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6827-33.


The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D.

Cancer Res. 2005 Aug 15;65(16):7462-9.


Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.


Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.

Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B.

Autophagy. 2008 Jul;4(5):659-68.


Enhanced radiation damage of tumor vasculature by mTOR inhibitors.

Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B.

Oncogene. 2005 Aug 18;24(35):5414-22.


Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.


SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation.

Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, Shyr Y, Wu H, Hallahan DE.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1197-203.


Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Spalding AC, Zeitlin BD, Wilder-Romans K, Davis ME, Nor JE, Lawrence TS, Ben-Josef E.

Transl Oncol. 2008 Dec;1(4):195-201.


Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.

Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M.

Cancer Res. 2010 Mar 1;70(5):1951-9. doi: 10.1158/0008-5472.CAN-09-3201.


The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.

Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.

Breast Cancer Res Treat. 2012 Jan;131(2):425-36. doi: 10.1007/s10549-011-1420-7.


Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.

Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L.

Anticancer Drugs. 2007 Aug;18(7):793-800.


Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O.

BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86.


DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.

Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, Hallahan DE.

Cancer Res. 2005 Jun 15;65(12):4987-92.


Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.

Thotala D, Craft JM, Ferraro DJ, Kotipatruni RP, Bhave SR, Jaboin JJ, Hallahan DE.

PLoS One. 2013 Jul 19;8(7):e69688. doi: 10.1371/journal.pone.0069688.

Items per page

Supplemental Content

Support Center